Workflow
These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings
RegeneronRegeneron(US:REGN) Benzinga·2025-08-04 18:05

Financial Performance - Regeneron Pharmaceuticals reported adjusted earnings of $12.89 per share, a 12% increase year-over-year, surpassing the consensus estimate of $8.57 [1] - The company achieved sales of $3.68 billion, reflecting a 4% year-over-year growth, exceeding the consensus of $3.29 billion [1] Future Guidance - For 2025, Regeneron expects a GAAP gross margin of approximately 83%, slightly lower than the previous guidance of 83%-84% [2] - The adjusted gross margin is anticipated to be around 86%, compared to the prior guidance of 86%-87% [2] Market Reaction - Following the earnings announcement, Regeneron Pharmaceuticals shares increased by 0.9%, trading at $563.62 [3] Analyst Ratings and Price Targets - Guggenheim analyst Yatin Suneja maintained a Buy rating and raised the price target from $810 to $815 [5] - RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and increased the price target from $688 to $695 [5] - Morgan Stanley analyst Matthew Harrison maintained an Overweight rating and raised the price target from $754 to $761 [5]